Phase 4 N=24 SMV + SOF With/Without RBV for IFN-II Patients With CHC
Hepatitis C
Primary: Sustained Viral Response — 13; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 EASY: Extended Access to Sollpura Over Years
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety, as Measured by Number of Participants With Adverse Events Including Clinical or Laboratory Abnormalities — 25; 9 Participants
Phase 4 N=30 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Diabetic Macular Edema · Epiretinal Membrane
Primary: Central Retinal Thickness — 350 micrometers
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Phase 4 N=116 Remifentanil and Glycemic Response in Cardiac Surgery
Heart Diseases · Hyperglycemia
Primary: Blood Glucose Values (More Than One ) > 180 mg% — 17; 33 Participants — p=0.001
Phase 4 N=200 Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein
Chronic Venous Insufficiency
Primary: Percentage of Participants Without Recurrent Clinical Symptoms of an Incompetent Greater Saphenous Vein After Treatment. — 79.3; 77.5 percentage of total participants
Phase 4 N=66 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Primary: Change From Baseline in American Urological Association Symptom Score — -14.7; -10.5 units on a scale
Phase 4 N=104 Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries
Athletic Injuries
Primary: Dermatologic Assessment at the Patch Application Site — 0.10; 0.04; 0.04; 0.06 Units on a scale
Phase 4 N=28 Implementation of PPI Medication PGX Testing
Gastroesophageal Reflux
Primary: Count of Patients Agreeing to Volunteer for the Study — 28 Participants
Phase 4 N=212 The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)
Coronary Artery Disease
Primary: Ticagrelor Pharmacokinetics — 3301; 2107 ng*hr/mL
Phase 4 N=13 Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total Score — 58.2; 53.5 units on a scale
Phase 4 N=30 An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
HIV-2 Infection
Primary: Death — 0 Participants
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
Phase 4 N=28 The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
Single Ventricle Fontan Palliation
Primary: Change in VO2 Max — 1.33; 0.745 Change in ml/kg min
Phase 4 N=110 Efficacy of Oral vs. Intravenous Acetaminophen
Postoperative Pain
Primary: Postoperative Pain Score on the Scale of 10 (0=No Pain and 10=Worst Pain) — 2; 2 units on a scale — p=0.252